Healthcare resources should be targeted to chemoprevention: the argument against.
Chemoprevention of prostate cancer is an attractive idea that appeals to many struggling with the treatment of this disease. Many details inherent in any preventive strategy must be considered before embarking on this course, no matter how seductive it may appear. Critical issues of effectiveness, cost, difficulties in implementation, side effects, duration of the preventive cycle, and public acceptance may thwart prevention of prostate cancer from being implemented in the near future.
Trachtenberg
J
J
Division of Urology, University of Toronto, Ont., Canada.
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000139:chemically induced; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D015276:Health Care Rationing / Q000191:economics; D006295:Health Resources / Q000191:economics; D006801:Humans; D008297:Male; D011322:Primary Prevention / Q000191:economics; D011471:Prostatic Neoplasms / Q000191:economics / Q000517:prevention & control*; D011639:Public Opinion
D016588:Anticarcinogenic Agents; D004791:Enzyme Inhibitors; D018120:Finasteride